Answers are grounded in this paper and cite their sources.
Conference presentations highlight advances in type 2 diabetes and nephropathy management, suggesting new treatment strategies.
Over the past five years, understanding metabolism related to managing type 2 diabetes mellitus and nephropathy has reached a level not seen in decades. The introduction of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide-1 (GLP-1) agonists, and selective nonsteroidal mineralocorticoid receptor antagonists (Finerenone) offers physicians new tools for nephroprotection programs. We present the posters from the conference.
No takes yet. Share an insight, caveat, or question.
SLANH (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: